Iohexol
Omnipaque (iohexol) is a small molecule pharmaceutical. Iohexol was first approved as Omnipaque 180 on 1985-12-26.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Omnipaque (discontinued: Oraltag)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Iohexol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OMNIPAQUE 9 | GE Healthcare | N-018956 RX | 2018-04-17 | 1 products, RLD, RS |
| OMNIPAQUE 12 | GE Healthcare | N-018956 RX | 2018-04-17 | 1 products, RLD, RS |
| OMNIPAQUE 140 | GE Healthcare | N-018956 RX | 1988-11-30 | 1 products, RLD, RS |
| OMNIPAQUE 180 | GE Healthcare | N-018956 RX | 1985-12-26 | 1 products, RLD, RS |
| OMNIPAQUE 240 | GE Healthcare | N-018956 RX | 1985-12-26 | 1 products, RLD, RS |
| OMNIPAQUE 300 | GE Healthcare | N-018956 RX | 1985-12-26 | 1 products, RLD, RS |
| OMNIPAQUE 350 | GE Healthcare | N-018956 RX | 1985-12-26 | 1 products, RLD, RS |
| OMNIPAQUE 300 | GE Healthcare | N-020608 RX | 1995-10-24 | 1 products |
| OMNIPAQUE 350 | GE Healthcare | N-020608 RX | 1995-10-24 | 1 products |
Show 4 discontinued
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
70 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 6 | — | — | 1 | — | 7 | ||
| Heart failure | D006333 | EFO_0003144 | I50 | — | 1 | — | 2 | — | 3 |
| Hiv | D006678 | O98.7 | — | — | — | 1 | 1 | 2 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | 1 | — | 1 |
| Hormone replacement therapy | D020249 | EFO_0003961 | Z79.890 | — | — | — | 1 | — | 1 |
| Transgenes | D019076 | — | — | — | 1 | — | 1 | ||
| Fibrosis | D005355 | — | — | — | 1 | — | 1 | ||
| Hypothyroidism | D007037 | EFO_0004705 | E03.9 | — | — | — | 1 | — | 1 |
| Coronary artery disease | D003324 | I25.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute kidney injury | D058186 | HP_0001919 | N17 | 2 | 1 | 1 | — | 4 | 8 |
| Shock | D012769 | R57.1 | — | — | 1 | — | — | 1 | |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic nephropathies | D003928 | EFO_0000401 | 3 | 2 | — | — | 4 | 7 | |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 2 | 1 | — | — | 3 | 5 |
| Diabetes complications | D048909 | 2 | 2 | — | — | 2 | 4 | ||
| Pediatric obesity | D063766 | 2 | 2 | — | — | 2 | 4 | ||
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 2 | 2 | — | — | 2 | 4 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 2 | 2 | — | — | 1 | 3 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | 1 | — | — | 1 | 2 |
| Weight loss | D015431 | HP_0001824 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | 3 | 4 |
| Glomerular filtration rate | D005919 | EFO_0005208 | 2 | — | — | — | — | 2 | |
| Leiomyoma | D007889 | HP_0000131 | D25 | 1 | — | — | — | — | 1 |
| Adenomyosis | D062788 | EFO_1001757 | N80.0 | 1 | — | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | 1 | — | — | — | — | 1 | ||
| Drug interactions | D004347 | 1 | — | — | — | — | 1 | ||
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | — | — | — | — | 1 |
| Pelvic neoplasms | D010386 | 1 | — | — | — | — | 1 | ||
| Abdominal neoplasms | D000008 | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | — | — | 3 | 3 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 2 | 2 |
| Autosomal dominant polycystic kidney | D016891 | EFO_1001496 | Q61.2 | — | — | — | — | 1 | 1 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 1 | 1 |
| Transsexualism | D014189 | F64.0 | — | — | — | — | 1 | 1 | |
| Critical illness | D016638 | — | — | — | — | 1 | 1 | ||
| Coronary angiography | D017023 | — | — | — | — | 1 | 1 | ||
| Colorectal neoplasms | D015179 | — | — | — | — | 1 | 1 | ||
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | — | — | 1 | 1 |
| Chronic renal insufficiency | D051436 | N18 | — | — | — | — | 1 | 1 |
Show 15 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | IOHEXOL |
| INN | iohexol |
| Description | Iohexol is a benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position. It has a role as a radioopaque medium, an environmental contaminant and a xenobiotic. It is an organoiodine compound and a benzenedicarboxamide. |
| Classification | Small molecule |
| Drug class | iodine-containing contrast media |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I |
Identifiers
| PDB | — |
| CAS-ID | 66108-95-0 |
| RxCUI | 5956 |
| ChEMBL ID | CHEMBL1200455 |
| ChEBI ID | 31709 |
| PubChem CID | 3730 |
| DrugBank | DB01362 |
| UNII ID | 4419T9MX03 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,726 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13,638 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more